for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ironwood Pharmaceuticals, Inc.

IRWD.OQ

Latest Trade

9.47USD

Change

-0.12(-1.25%)

Volume

1,101,668

Today's Range

9.36

 - 

9.74

52 Week Range

8.40

 - 

19.36

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.59
Open
9.56
Volume
1,101,668
3M AVG Volume
40.97
Today's High
9.74
Today's Low
9.36
52 Week High
19.36
52 Week Low
8.40
Shares Out (MIL)
156.50
Market Cap (MIL)
1,482.01
Forward P/E
71.47
Dividend (Yield %)
--

Next Event

Q3 2019 Ironwood Pharmaceuticals Inc Earnings Release

Latest Developments

More

Ironwood Pharmaceuticals, AstraZeneca Amend Linzess Collaboration In China

Ironwood Pharmaceuticals Announces Pricing Of Upsized $350 Million Convertible Senior Notes Offering

Ironwood Pharmaceuticals Announced Proposed Offering Of $330 Million Of Convertible Senior Notes

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).

Industry

Biotechnology & Drugs

Contact Info

301 Binney St

+1.617.6217722

http://www.ironwoodpharma.com/

Executive Leadership

Julie H. McHugh

Independent Chairman of the Board

Mark Mallon

Chief Executive Officer, Director

Gina Consylman

Chief Financial Officer, Senior Vice President

William Huyett

Chief Operating Officer

Thomas A. McCourt

Senior Vice President - Marketing and Sales, Chief Commercial Officer

Key Stats

2.38 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.3K

2017

0.3K

2018

0.3K

2019(E)

0.4K
EPS (USD)

2016

-0.560

2017

-0.930

2018

-0.950

2019(E)

0.142
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.03
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-54.78
Return on Equity (TTM)
-42.70

Latest News

BRIEF-Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving Linzess Patent Litigation

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH AUROBINDO PHARMA RESOLVING LINZESS (LINACLOTIDE) PATENT LITIGATION

BRIEF-Ironwood Pharmaceuticals To Separate Into Two Independent, Publicly Traded Companies

* IRONWOOD PHARMACEUTICALS ANNOUNCES INTENT TO SEPARATE SOLUBLE GUANYLATE CYCLASE (SGC) BUSINESS FROM COMMERCIAL AND GASTROINTESTINAL BUSINESS

BRIEF-Ironwood Pharmaceuticals Reports Q1 Loss Per Share Of $0.29

* IRONWOOD PHARMACEUTICALS PROVIDES FIRST QUARTER 2018 INVESTOR UPDATE

BRIEF-Ironwood Announces Director Nomination From Sarissa Capital

* RECEIVED NOTICE FROM SARISSA CAPITAL MANAGEMENT LP OF INTENTION TO NOMINATE ALEX DENNER TO STAND FOR ELECTION Source text for Eikon: Further company coverage:

BRIEF-Ironwood Pharmaceuticals Qtrly GAAP Net Income Per Share $0.08

* EXPECTS TO USE LESS THAN $75 MILLION IN CASH FOR OPERATIONS IN 2018 Source text for Eikon: Further company coverage:

BRIEF-Ironwood Pharmaceuticals Implements Reduction In Field-Based Workforce

* SAYS COMMENCED AN INITIATIVE TO EVALUATE OPTIMAL MIX OF INVESTMENTS FOR LESINURAD FRANCHISE FOR UNCONTROLLED GOUT

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

BRIEF-Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million For FY Ended Dec 31, 2017

* IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION FOR FY ENDED DEC 31, 2017

BRIEF-Ironwood Reports Top-Line Phase IIa Data For IW-1973

* IRONWOOD REPORTS TOP-LINE PHASE IIA DATA FOR IW-1973 DEMONSTRATING POSITIVE CARDIOVASCULAR, METABOLIC AND ENDOTHELIAL EFFECTS

BRIEF-Ironwood Pharmaceuticals Strengthens Executive Leadership Team

* IRONWOOD PHARMACEUTICALS STRENGTHENS EXECUTIVE LEADERSHIP TEAM

BRIEF-Ironwood Pharma files for potential mixed shelf offering

* Ironwood Pharmaceuticals Inc files for potential mixed shelf offering; size not disclosed - SEC filing Source text: (http://bit.ly/2h08KF7) Further company coverage:

BRIEF-Ironwood Pharmaceuticals Q3 non-GAAP loss per share $0.18

* Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S

BRIEF-Ironwood Pharma says CFO Tom Graney will leave company

* Ironwood Pharmaceuticals Inc- Tom Graney, chief financial officer will leave company

FDA approves Ironwood Pharma's gout drug

Ironwood Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) approved its oral drug to treat a condition associated with gout.

BRIEF-Ironwood Pharma announces FDA approval of Duzallo to treat hyperuricemia in patients with uncontrolled gout

* Ironwood Pharmaceuticals announces FDA approval of Duzallo (Lesinurad And Allopurinol) for the treatment of hyperuricemia in patients with uncontrolled gout

BRIEF-Ironwood Pharmaceuticals Q2 loss per share $0.30

* Ironwood Pharmaceuticals provides second quarter 2017 investor update

Ironwood reflux drug appears effective, safe in midstage trial

Ironwood Pharmaceuticals Inc said on Thursday its potential blockbuster drug for gastroesophageal reflux disease (GERD) not controlled by current medicines significantly reduced heartburn severity and regurgitation frequency, meeting the main goals of a midstage trial.

BRIEF-Ironwood Pharmaceuticals reports Q1 loss per share of $0.36

* Ironwood pharmaceuticals provides first quarter 2017 investor update

BRIEF-Ironwood pharmaceuticals qtrly loss per share $0.09

* Ironwood Pharmaceuticals Inc - ironwood expects 2017 research and development expenses to be in range of $145 million to $160 million.

BRIEF-Ironwood Pharmaceuticals and Allergan entered into amendment to license agreement, dated April 30, 2009

* Ironwood Pharmaceuticals Inc - Co and Allergan Pharmaceuticals International Ltd. entered into amendment to license agreement, dated April 30, 2009

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up